General MedicationsORALGeneric

STAVUDINE; LAMIVUDINE; NEVIRAPINE

Standard Dose

40MG; 150MG; 200MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: None (Tentative Approval)

Summary

Approval overview STAVUDINE; LAMIVUDINE; NEVIRAPINE is listed in Drugs@FDA under application 022346 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient STAVUDINE; LAMIVUDINE; NEVIRAPINE Form and strength TABLET; ORAL - 40MG; 150MG; 200MG Sponsor PHARMACARE LTD Submission history Latest submission status date: 2009-02-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview STAVUDINE; LAMIVUDINE; NEVIRAPINE is listed in Drugs@FDA under application 022346 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient STAVUDINE; LAMIVUDINE; NEVIRAPINE Form and strength TABLET; ORAL - 40MG; 150MG; 200MG Sponsor PHARMACARE LTD Submission history Latest submission status date: 2009-02-27 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.